Christian Briggs, MD
Ophthalmology · Muncie, INNPI 1982164216
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,201 of the $4,680 with a category attached, or 68.4%. 15 manufacturers reported payments, led by Alcon at 57.3% of the total. 2025 is the largest year on record at $2,172, more than ten times the $100 reported in 2020.
Across 58 payments — averaging $80.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$3K
- Johnson & Johnson Surgical Vision, Inc.$301
- AbbVie$275
- Bausch & Lomb Americas Inc.$263
- Genentech USA, Inc.$235
- Glaukos Corporation$170
- plus $753 from 9 others
What the payments were for
- Travel & lodging$1,37829%
- Food & beverage$3,20168%
- Education$1002%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 21 | $2,682 |
| Johnson & Johnson Surgical Vision, Inc. | 4 | $301 |
| AbbVie(2 entities) | 4 | $275 |
| Bausch & Lomb Americas Inc. | 6 | $263 |
| Genentech USA, Inc. | 5 | $235 |
| Glaukos Corporation | 3 | $170 |
| Biotissue Holdings Inc. | 4 | $144 |
| Rxsight Inc | 1 | $131 |
| Apellis Pharmaceuticals, Inc. | 1 | $122 |
| Ocular Therapeutix, Inc. | 1 | $111 |
| Sight Sciences, Inc. | 3 | $103 |
| Dompe US, Inc. | 2 | $91 |
| Astellas Pharma US Inc | 1 | $26 |
| Tarsus Pharmaceuticals, Inc. | 1 | $21 |
| NEW World Medical,inc. | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Clareon$1,748
- Unity$1,505
- Wavelight Refractive Suite$1,378
- Voyager DSLT$1,378
- LenSx$1,378
- enVista MX60 IOL$250
- RXSIGHT CONTACT LENS$131
- RXSIGHT INJECTOR CARTRIDGE$131
- RXSIGHT INJECTOR HANDPIECE$131
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$131
- LIGHT ADJUSTABLE LENS (LAL)$131
- AMO PHACO NEEDLE$131
- Precision 1$128
- DURYSTA$125
- enVista Aspire IOL$125
- AcrySof IQ PanOptix$125
- VABYSMO$125
- Hydrus Microstent$123
- Syfovre$122
- DEXTENZA$111
How this compares
$4,680 in reported general payments places this provider in the 80th percentile of 266 ophthalmology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 15 | $9,514 |
| Prednisolone Acetate | 137 | $5,601 |
| Ketorolac Tromethamine | 117 | $2,524 |
| Ofloxacin | 91 | $967 |
| Latanoprost | 112 | $873 |
| ErythromycinErythromycin Base | 74 | $856 |
| ValacyclovirValacyclovir Hcl | 18 | $835 |
| Timolol Maleate | 44 | $373 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 29 | $369 |
| Doxycycline Hyclate | 32 | $261 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 22 | $223 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis | $275 | $9,51415 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 266 ophthalmology providers in Indiana.
Other ophthalmology in Muncie
- Michael ScanameoMuncie$9K
- Michael HodkinMuncie$4K
- Shamik BafnaLafayette$505K
- Kevin WaltzIndianapolis$199K
- Janet HummerIndianapolis$96K
- Francis PriceIndianapolis$67K
- Omar DukarEvansville$43K
- Gerald RoperBatesville$34K
- Dwight SilveraEvansville$28K
- Michael OrrIndianapolis$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.